• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

News

RDD 2020 switches to digital format

Due to public gathering and travel restrictions imposed in response to the COVID-19 pandemic, the organizers of RDD 2020 have made the decision to cancel the RDD 2020 conference that was scheduled to take place April 26-May 1, 2020 in Palm Desert, California; however, RDD 2020 will go ahead in a digital format of some sort. The associated IPAC-RS symposium that was … [Read more...] about RDD 2020 switches to digital format

FDA lists Arcapta, Seebri, and Utibron Neohalers as discontinued (updated)

According to the FDA, three DPIs marketed by Sunovion in the US have been discontinued as of March 10, 2020. Sunovion acquired the US rights to Utibron (indacaterol/glycopyrrolate) Neohaler, Seebri (glycopyrrolate) Neohaler, and Arcapta (indacaterol) Neohaler from Novartis in December 2016. The inhalers are marketed elsewhere as Ultibro Breezhaler, Seebri Breezhaler, … [Read more...] about FDA lists Arcapta, Seebri, and Utibron Neohalers as discontinued (updated)

Engage Therapeutics reports positive results from Phase 2 study of Staccato alprazolam for epileptic seizures

Engage Therapeutics said that the Phase 2b StATES (Staccato Alprazolam Terminates Epileptic Seizures) trial of Staccato inhaled alprazolam in epilepsy patients has met its primary endpoint, terminating seizure activity within two minutes of dosing with no recurrence in 50 of 76 patients. Engage had announced the initiation of the study in April … [Read more...] about Engage Therapeutics reports positive results from Phase 2 study of Staccato alprazolam for epileptic seizures

Fluidda’s Broncholab FRI platform cleared by FDA for clinical use

Functional respiratory imaging (FRI) company Fluidda announced that the FDA has cleared the company's Broncholab FRI platform for use in clinical settings. According to the company, Broncholab can provide much more accurate information about patient-specific regional lung function than conventional test methods like spirometry, allowing for better diagnosis and … [Read more...] about Fluidda’s Broncholab FRI platform cleared by FDA for clinical use

Senzer obtains IND data package for inhaled dronabinol from Insys Therapeutics

According to Senzer, the company has obtained the IND application and data package for its inhaled dronabinol from its former partner, Insys Therapeutics, and will now move ahead with development for the treatment of side effects from chemotherapy and for neuropathic pain. Insys filed for bankruptcy in June 2019. Senzer partnered with Insys in 2015 to develop … [Read more...] about Senzer obtains IND data package for inhaled dronabinol from Insys Therapeutics

Mylan launches Wixela Inhub in Canada

Mylan Pharmaceuticals has announced the launch of the Wixela Inhub fluticasone propionate/salmeterol DPI in Canada. According to the company, Health Canada approved Wixela Inhub, a generic version of Advair Diskus, in January 2020 for asthma and COPD. The inhaler will be available in 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg strengths for asthma and 250 … [Read more...] about Mylan launches Wixela Inhub in Canada

Mark Bridgewater joins Vectura as Chief Commercial Officer

Vectura has announced the appointment of Mark Bridgewater as Chief Commercial Officer, a position the company said it has created as it "continues with its strategy to become a leading inhalation specialist in the pharmaceutical services space." In February 2020, the company announced the appointment of Sharon Johnson as Executive VP for Delivery Management, another … [Read more...] about Mark Bridgewater joins Vectura as Chief Commercial Officer

FDA issues new and revised product specific guidances for a number of generic OINDPs

The FDA has announced the publication of a batch of new and revised product specific guidances for development of generic versions of a number of drugs, including a number of inhaled and nasal drug products, . One of the new guidances is for generic sumatriptan succinate nasal powder. Onzetra Xsail intranasal sumatriptan was approved by the FDA in January 2016 for … [Read more...] about FDA issues new and revised product specific guidances for a number of generic OINDPs

Virpax announces completion of pre-IND meeting for its intranasal enkephalin

Virpax Pharmaceuticals has announced the successful completion of a pre-IND meeting with the FDA regarding the company's NES100 intranasal enkephalin formulation for the management of acute and chronic pain. NES100 is a molecular envelope technology (MET) formulation licensed from Nanomerics and is delivered via a cartridge-based device. In January 2020, Virpax … [Read more...] about Virpax announces completion of pre-IND meeting for its intranasal enkephalin

Neurelis launches Valtoco nasal spray in the US

Neurelis has announced the launch of Valtoco diazepam nasal spray for the treatment of seizure clusters in the US. The FDA approved Valtoco for the treatment of acute repetitive seizures in epilepsy patients aged 6 and older in January 2020. According to the company, patients can now obtain Valtoco through Maxor Specialty Pharmacy, which has already started filling … [Read more...] about Neurelis launches Valtoco nasal spray in the US

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 152
  • Page 153
  • Page 154
  • Page 155
  • Page 156
  • Interim pages omitted …
  • Page 417
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews